Pharmacokinetics
Conditions
Keywords
Alprazolam, Alprazolam extended release, Clonazepam, Pharmacokinetics, Mexican population, Healthy
Brief summary
To estimate the pharmacokinetics of single doses of benzodiazepines in Mexican adult healthy volunteers: a) alprazolam tablet extended release, b) alprazolam tablet immediate release, and clonazepam tablet.
Detailed description
To determine pharmacokinetics of alprazolam and clonazepam in Latin-American population; in Mexico, both drugs are still widely used as first or second choice in the treatment of anxiety disorders.
Interventions
DRUGAlprazolam
Administration of a single oral dose tablet of 1 mg of alprazolam immediate release on Day 1 morning, between 8-9 am with 250 ml of water in at least 10 hours of fasting conditions
DRUGAlprazolam XR
Administration of a single oral dose tablet of 1 mg of alprazolam modified release on Day 1 morning, between 8-9 am with 250 ml of water in at least 10 hours of fasting conditions
DRUGClonazepam
Administration of a single oral dose of two tablets of 0.5 mg of clonazepam on Day 1 morning, between 8-9 am with 250 ml of water in at least 10 hours of fasting conditions
Sponsors
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
18 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy male or female volunteers aged between 18 and 40 years old.
Exclusion criteria
* Subjects presenting changes on their vital signs constants registered at volunteers' screening. * Volunteers with any of the following: noncompliance of proposed inclusion criteria; requiring another drug product throughout the study conduction; pregnant or nursing females; history of cardiovascular, renal, hepatic, muscular, metabolic, gastrointestinal, neurological, endocrine, psychiatric, hematopoietic or any other anemia kind, disease, asthma, or organic disorder; history of dyspepsia, gastritis, esophagitis, duodenal or gastric ulcer or any condition possibly affecting drug absorption; history of acute narrow or glaucoma; exposed to drug products known as hepatic enzyme or inductors; who had received any drug product within 14 days or 5 half lives; who had been hospitalized due to any problem within 60 days prior to study start; history of sensitivity to BZD; who had drink alcohol or any beverage containing xanthines or who had taken smoked food or grapefruit juice within 72 hours prior to start hospitalization period, who had blood donated or lost 450 mL or more within 60 days prior to study start; requiring any special diet regardless the cause.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| AUC last: Area under the curve of plasma concentration from administration up to time t (last sampling timepoint) calculated by trapezoid method. | Sampling times: 0 to 96 hours |
| AUC inf: Area under the curve of plasma concentration from administration up to infinitum extrapolated time. | Sampling times: 0 to 96 hours |
| Cmax: Maximum plasma concentration graphically obtained, based on plasma concentration versus time profile. | Sampling times: 0 to 96 hours |
| t 1/2: Half life time. | Sampling times: 0 to 96 hours |
| Tmax: Time from administration up to maximum plasma concentration, graphically obtained based on plasma concentration versus time profile. | Sampling times: 0 to 96 hours |
Secondary
| Measure | Time frame |
|---|---|
| No Secondary Outcomes | — |
Countries
Mexico
Outcome results
None listed